Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase
- PMID: 8524223
- PMCID: PMC230911
- DOI: 10.1128/MCB.15.12.6582
Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase
Abstract
Nyk/Mer is a recently identified receptor tyrosine kinase with neural cell adhesion molecule-like structure (two immunoglobulin G-like domains and two fibronectin III-like domains) in its extracellular region and belongs to the Ufo/Axl family of receptors. The ligand for Nyk/Mer is presently unknown, as are the signal transduction pathways mediated by this receptor. We constructed and expressed a chimeric receptor (Fms-Nyk) composed of the extracellular domain of the human colony-stimulating factor 1 receptor (Fms) and the transmembrane and cytoplasmic domains of human Nyk/Mer in NIH 3T3 fibroblasts in order to investigate the mitogenic signaling and biochemical properties of Nyk/Mer. Colony-stimulating factor 1 stimulation of the Fms-Nyk chimeric receptor in transfected NIH 3T3 fibroblasts leads to a transformed phenotype and generates a proliferative response in the absence of other growth factors. We show that phospholipase C gamma, phosphatidylinositol 3-kinase/p70 S6 kinase, Shc, Grb2, Raf-1, and mitogen-activated protein kinase are downstream components of the Nyk/Mer signal transduction pathways. In addition, Nyk/Mer weakly activates p90rsk, while stress-activated protein kinase, Ras GTPase-activating protein (GAP), and GAP-associated p62 and p190 proteins are not activated or tyrosine phosphorylated by Nyk/Mer. An analysis comparing the Nyk/Mer signal cascade with that of the epidermal growth factor receptor indicates substrate preferences by these two receptors. Our results provide a detailed description of the Nyk/Mer signaling pathways. Given the structural similarity between the Ufo/Axl family receptors, some of the information may also be applied to other members of this receptor tyrosine kinase family.
Similar articles
-
Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells.Mol Cell Biol. 1993 Oct;13(10):6572-85. doi: 10.1128/mcb.13.10.6572-6585.1993. Mol Cell Biol. 1993. PMID: 7692230 Free PMC article.
-
Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase.J Biol Chem. 1996 Aug 2;271(31):18355-62. doi: 10.1074/jbc.271.31.18355. J Biol Chem. 1996. PMID: 8702477
-
Biological function of PDGF-induced PI-3 kinase activity: its role in alpha PDGF receptor-mediated mitogenic signaling.J Cell Biol. 1994 Oct;127(2):479-87. doi: 10.1083/jcb.127.2.479. J Cell Biol. 1994. PMID: 7929590 Free PMC article.
-
CSF-1 signal transduction.J Leukoc Biol. 1997 Aug;62(2):145-55. doi: 10.1002/jlb.62.2.145. J Leukoc Biol. 1997. PMID: 9261328 Review.
-
Growth and differentiation signals regulated by the M-CSF receptor.Mol Reprod Dev. 1997 Jan;46(1):96-103. doi: 10.1002/(SICI)1098-2795(199701)46:1<96::AID-MRD15>3.0.CO;2-1. Mol Reprod Dev. 1997. PMID: 8981370 Review.
Cited by
-
TAM receptors in leukemia: expression, signaling, and therapeutic implications.Crit Rev Oncog. 2011;16(1-2):47-63. doi: 10.1615/critrevoncog.v16.i1-2.60. Crit Rev Oncog. 2011. PMID: 22150307 Free PMC article.
-
Targeting the TAM Receptors in Leukemia.Cancers (Basel). 2016 Nov 8;8(11):101. doi: 10.3390/cancers8110101. Cancers (Basel). 2016. PMID: 27834816 Free PMC article. Review.
-
MerTK is a novel therapeutic target in gastric cancer.Oncotarget. 2015 Apr 20;8(57):96656-96667. doi: 10.18632/oncotarget.3750. eCollection 2017 Nov 14. Oncotarget. 2015. PMID: 29228560 Free PMC article.
-
The receptor tyrosine kinase MerTK activates phospholipase C gamma2 during recognition of apoptotic thymocytes by murine macrophages.J Leukoc Biol. 2004 Apr;75(4):705-13. doi: 10.1189/jlb.0903439. Epub 2004 Jan 2. J Leukoc Biol. 2004. PMID: 14704368 Free PMC article.
-
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.Cancers (Basel). 2021 Nov 11;13(22):5639. doi: 10.3390/cancers13225639. Cancers (Basel). 2021. PMID: 34830794 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous